article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog: Drug Discovery

Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field. In October, FDA announced seven new clinical trial grants awarded in fiscal year (FY) 2024 – including one for a Phase 3 trial – totaling $17.2

article thumbnail

Navigating the Clinical Development Landscape: Insights for Success in 2024

Cytel

After explosive and frenetic activity in the clinical trial industry during the COVID era, the past two years have seen challenging market dynamics and a drop-off in activity. Every one of us working in clinical development has felt this slowdown, but as we begin 2024, there is reason for optimism.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sentiment & Themes Emerging From JPM 2024

LifeSciVC

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Figure 2 shows pipelines across modalities for some of the competitive targets today. reduce on-target anemia).

article thumbnail

ScienceSaturday: March 16, 2024

KIF1A

While genetic disorders like KAND make up only a small part of this number, this represents the need for increased investment in neuroscience research and clinical development. Read the Article The post ScienceSaturday: March 16, 2024 appeared first on KIF1A.

Disease 105
article thumbnail

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis

Covalent Modifiers

Hopkins Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.4c00220 Purgett, Joseph C. Santoro, Jurgen Schulz, Simone Sciabola, Hao Tang, H. George Vandeveer, Ti Wang, Zain Yousaf, Christopher J. Helal, and Brian T.

Treatment 208
article thumbnail

Simpler Clinical Development From Day Dot

Alta Sciences

Simpler Clinical Development From Day Dot blussier Fri, 06/21/2024 - 19:10 HTML Connecting the Dots With Comprehensive CRO Solutions When you CONNECT THE DOTS, you open a world of possibilities. At Altasciences, we connect the dots, so you don’t have to.

article thumbnail

Five Predictions for the Biopharma and Biotech Industries in 2024

PPD

As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Five Predictions for the Drug Development Industry in 2024 1.